Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

Sponsor: Georg Hess, MD
Study ID: NCT02099292
Phase: PHASE2
Status: Completed

Conditions

Relapsed Non-Hodgkin-Lymphoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - 65 Years
Healthy Volunteers: Not accepted

Interventions

Rituximab and DexaBEAM — DRUG
combination treatment

Study Details

The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and indolent lymphoma.

Key Dates

Start date: May 31, 2001
Status verified: Mar 2014
Primary completion: May 31, 2005
Completion: Mar 31, 2014

Study Design

Enrollment: 103 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Rituximab and DexaBEAM
Rituximab and DexaBEAM

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: five years follow up ]